Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow, that's extremely relevant to the link I posted earlier. That's huge.
I hope this is something ACTC can and will apply for so that mankind can benefit from these type of treatments sooner than expected.
I feel a strong finish coming on!!
I second that.
I hope this is something ACTC plans on benefiting from.
The scheme will begin taking applications from companies from early April 2014. MHRA will provide advice on the scheme when it is launched and we look forward to receiving applications from then.
- See more at: http://investorstemcell.com/stem-cell-research/uk-govt-announces-early-access-program-for-treatment-of-life-threatening-or-seriously-debilitating-condition/#sthash.zV3qH1XO.dpuf
I'm sorry I don't understand your question. Can you rephrase that in layman's terms please.
Maybe because they were links to icell... I'll try reporting the links to direct PRs
Off*
With the big sell of in the major exchanges today.... BioHeart holding strong is a key clue to the bull indication of said stock. IMO.
Lanza is with ACTC. That is what it is, until it isn't.
Yes that's the same gentleman from Maxim. .45 price target for ACTC. It's coming with TLD. The wait is painful but the reward is bliss.
No problem guys. GLTA
Here's the link to my post where I introduced the employee count at 42.
http://arminvestorday.com/company-presentations/#act
Did someone really just pick up shares for under .04?
Just because an announcement on full enrollment wasn't made does not mean full enrollment has not occurred. All will be disclosed at the end of this month IMO. You don't want to watch the train take off without you. Buy your ticket to ride before it's too late.
http://stemcellceo.com/wp/bioheart/thank-you/
Our upcoming 10K (which will be filed on-time prior to March 31st) will outline the results of our recent commercial programs, for example:
Our physician training programs in the field of cellular medicine continues at a fast pace
Partnering with Anosis Biomedical Limited to distribute Bioheart therapies to patients in the Middle East and surrounding areas. Bioheart announced that its first successful adipose derived stem cell (ADSC) implantation was performed in Azerbaijan at Baku Central Military Hospital. Azerbaijan is the largest country in the region located at the crossroads of Western Asia and Eastern Europe.
Bioheart announced exclusive license in veterinary medicine for patents for cancer-related immunotherapy products from inventor Allan Wu, M.D.
Bioheart has extended licenses of electrical stimulation patents with Airspeed for MyoStim product line. Bioheart has successfully been treating patients for a range of conditions for almost 15 years with our autologous cellular products.
ARM’s Regen Med Investor Day is a full-day conference combining discussions between key opinion leaders, top analysts and senior executives with an afternoon of presentations by the field’s most promising companies.
Wednesday – March 26, 2014
PRESENTATION
Ted Myles, Interim President, CFO & EVP of Corporate Development
4:30pm | Main Bar Room
GENERAL INFORMATION
Stock Symbol: OTCBB: ACTC
Headquarters: Marlborough, MA
Number of Full-Time Employees: 42
Company Website: www.advancedcell.com
PIPELINE INFORMATION
Phase I/II Trials: 2 Total - Stargardt’s Macular Dystrophy (SMD), Dry Age-Related Macular Degeneration (Dry AMD)
Bioheart's Kristin Comella Named to 50 Most Influential People on Stem Cells
SUNRISE, FL--(Marketwire - Mar 12, 2013) - Bioheart Inc. (OTCQB: BHRT) announced that Bioheart's Chief Science Officer, Kristin Comella was named to the 50 most influential people on stem cells. The World Stem Cell Regenerative Medicine Congress asked the international stem cell community to compile a comprehensive list of the top 50. These personalities were picked based on their career achievements and dedication to the field of regenerative medicine. Ms. Comella debuted at #24 on the list.
Bioheart's president and CEO, Mike Tomas, said, "Bioheart is honored to have Kristin Comella leading our exciting platform of regenerative medicine products. Her dedication and accomplishments in the field are justifiably recognized by her peers."
I'm aware it's already happened, I'm referring to the separation.
Crux=Cross
The lines can cross but the actual Crux needs to form.
http://stockcharts.com/c-sc/sc?s=BHRT&p=D&b=5&g=0&i=t10329992158&r=1394561364955
"Golden Crux" forming nicely??
After the dust settles (profit takers) in almost all stocks that "blow up", as more investors realize the "long" potential in the stock... The price corrects itself with a casual climb back up to or near the "blow up" price. My opinion through observation.
Just traders satisfied with current profits. It will slowly rise back up IMO
Apparently he's 100K shy of 14M
http://ih.advfn.com/p.php?pid=nmona&article=61394184&xref=newsalert
Can someone tell me what this means please.
I cannot believe anyone would fall for the quicksand!!! Stop selling at lower and lower levels!!!!!
@ .033
http://www.digitaljournal.com/pr/1780804
Global stem cells group has an agreement to offer BioHeart products right?
Only 10K that matters.
Don't live in the past stocks are about the future.
Here's the bottom half of our CEO's recent blog posted on MARCH 7th
Our upcoming 10K (which will be filed on-time prior to March 31st) will outline the results of our recent commercial programs, for example:
\- Our physician training programs in the field of cellular medicine continues at a fast pace.
- Partnering with Anosis Biomedical Limited to distribute Bioheart therapies to patients in the Middle East and surrounding areas. Bioheart announced that its first successful adipose derived stem cell (ADSC) implantation was performed in Azerbaijan at Baku Central Military Hospital. Azerbaijan is the largest country in the region located at the crossroads of Western Asia and Eastern Europe.
- Bioheart announced exclusive license in veterinary medicine for patents for cancer-related immunotherapy products from inventor Allan Wu, M.D.
- Bioheart has extended licenses of electrical stimulation patents with Airspeed for MyoStim product line. Bioheart has successfully been treating patients for a range of conditions for almost 15 years with our autologous cellular products.
On other community news, I recently made my first public appearance since surgery as the moderator of Florida International University’s Entrepreneurs in Tech Panel. The Pino Global Entrepreneurship Center’s mission is to foster entrepreneurship throughout South Florida. The Center provides FIU and local communities with the knowledge and networks that enable them to reach their entrepreneurial objectives of designing, launching, and nurturing successful new ventures and assisting established innovative enterprises in moving to the next level. Our intention is to form and lead an alliance of related regenerative medicine companies in the area and work in tandem to more expeditiously bring these therapies to market.
We strongly believe that Bioheart’s efforts will prove to be invaluable towards accomplishing our mission to find a treatment for the unmet medical needs that afflict millions of individuals. As we bring our technology to market we realize ongoing communication with you–our shareholders and friends of the firm is important and key.
Thank you for your continued support and as always please reach out to me via email with your comments or questions.
Warm Regards,
Mike Tomás and the Bioheart Team
People created the chart indicators... And You have just created a conundrum.
Nice post.
Steady climb. Blog set the pace IMO
Our upcoming 10K (which will be filed on-time prior to March 31st) will outline the results of our recent commercial programs
I hope they report a substantial increase in rev.
Sounds like they will.
We should have a strong finish compared to the days low IMO. No one wants to be sitting on the sidelines over the weekend into Monday.
Not a problem. If it seems as if the lead was taken from BioHeart it will only be regained once they announce complete enrollment of phase 3 mirror trial for Myocell.
Thanks Gsdubb, found it.
Fortnightly Thoughts Goldman Sachs.
We highlight several pipeline drugs that may improve the current standard of care in HF....Stem cell therapies, e.g. MyoCell from Bioheart that uses a patient’s own muscle stem cells to repair heart muscle.
What page?
http://www.digitaljournal.com/pr/1777135
ACT (advanced cell technology) presenting this month
Exactly the kind of answer I expected.
BHRT has nothing to do with what you are alleging and is being alleged. I suggest you do some real DD if you're invested in this stock. Only facts matter. Here are a couple of links to get you started.
http://www.bioheartinc.com/News-Events/NewsReleases
http://stemcellceo.com/wp/bioheart/
BioHeart is the real deal, a real company working on capitalizing on the future of medicine. A paradigm shift worth billions.
Success is where opportunity meets preparation. BioHeart has been preparing for the age and opportunity of regenerative medicine and the time is among us. IMO but I'm not the only one that thinks so... Just "google" stem cell therapy, stem cell research, or regenerative medicine... Don't forget to click on the News tab. GLTA